Immuno-Oncology | Specialty

Bladder Cancer: Monoclonal Antibodies Under Investigation

March 16th 2017

BCG-Refractory Superficial Bladder Cancer

March 16th 2017

Bladder Cancer: Immunotherapy in the Perioperative Setting

March 16th 2017

Combination Trials in Advanced Bladder Cancer

March 16th 2017

Immunotherapy Toxicity Management in Bladder Cancer

March 16th 2017

Update on Durvalumab for Metastatic Bladder Cancer

March 16th 2017

Chemotherapy Following Immunotherapy in Bladder Cancer

March 16th 2017

Activity of Immunotherapy in the Frontline Setting

March 16th 2017

Bladder Cancer: Real-World Experience With Immunotherapy

March 16th 2017

FDA Approval of Atezolizumab for Advanced Bladder Cancer

March 16th 2017

PD-L1 Expression in Bladder Cancer

March 16th 2017

Prognostic Subgroups in Advanced Bladder Cancer

March 16th 2017

Historic Perspective on Treatment of Bladder Cancer

March 16th 2017

Researcher Aims to Advance Immunotherapy Impact in Bladder Cancer

March 15th 2017

Arlene O. Siefker-Radtke, MD, discusses the exciting advances in the bladder cancer field, why researchers should move past PD-L1 as a biomarker, and what combinations can be expected to move through the pipeline next.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma

March 15th 2017

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

FDA Approves Pembrolizumab for Hodgkin Lymphoma

March 15th 2017

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy.

Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC Success

March 14th 2017

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer

March 13th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

March 13th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.